China-based provider of genomic services and solutions Novogene and US firm Illumina have entered an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing (NGS) technology.
The deal, which will focus on providing the most advanced and integrated sequencing solutions to the clinical market, signals the importance of genomic applications to improve healthcare in China.
NGS technology has progressed rapidly over the last few years and is regarded as an essential factor for enabling precision medicine.
Under the deal, the companies will jointly develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.
Novogene founder Dr Ruiqiang Li said: "As a global provider of high-quality genomic services and leading edge bioinformatics solutions, Novogene is pleased to partner with Illumina to advance the application of NGS technology in precision medicine.
"As the first company in China to purchase Illumina's HiSeq X Ten system and the largest provider of Illumina-based sequencing capacity in China, Novogene welcomes this opportunity to improve the quality of care enjoyed by the Chinese people."
Technology from Illumina sequencers will be combined with Novogene's advanced clinical application development capabilities.
Novogene will provide its nucleic acid extraction, library preparation and data analysis software, while Illumina will provide NGS instrument components and related reagents.